BACKGROUND: Participation in an exercise trial is a major commitment for cancer survivors, but few exercise trials have evaluated patient satisfaction with trial participation. PURPOSE: To examine patient satisfaction with participation in the Healthy Exercise for Lymphoma Patients (HELP) Trial and to explore possible determinants. METHODS: The HELP Trial randomized 122 lymphoma patients to 12 weeks ofsupervised aerobic exercise training (AET; n = 60) or to usual care (UC; n = 62), with the option of participating in a 4-week posttrial exercise program. At the 6-month follow-up assessment, participants evaluated their overall trial satisfaction. RESULTS:Personal satisfaction with trial participation was strongly influenced by group assignment with participants randomized to AET reporting participation to be more rewarding (p < 0.001) and personally useful (p < 0.001) than participants randomized to UC. UC participants who completed the optional 4-week posttrial exercise program reported participation to be more rewarding (p = 0.008) and personally useful (p < 0.001) than UC participants who declined the program. LIMITATIONS: The study is limited by the lack of a validated measure of participant satisfaction, and the fact that the offer of participation in the posttrial exercise program to the UC group was not randomized. CONCLUSIONS:Lymphoma patients randomized to UC viewed it as less rewarding and personally useful despite being offered a 4-week posttrial exercise program. UC participants who completed the 4-week program reported personal satisfaction levels similar to the AET group; however, the causal direction of this association is unknown. Researchers should continue to evaluate participant satisfaction in exercise trials.
RCT Entities:
BACKGROUND: Participation in an exercise trial is a major commitment for cancer survivors, but few exercise trials have evaluated patient satisfaction with trial participation. PURPOSE: To examine patient satisfaction with participation in the Healthy Exercise for LymphomaPatients (HELP) Trial and to explore possible determinants. METHODS: The HELP Trial randomized 122 lymphomapatients to 12 weeks of supervised aerobic exercise training (AET; n = 60) or to usual care (UC; n = 62), with the option of participating in a 4-week posttrial exercise program. At the 6-month follow-up assessment, participants evaluated their overall trial satisfaction. RESULTS: Personal satisfaction with trial participation was strongly influenced by group assignment with participants randomized to AET reporting participation to be more rewarding (p < 0.001) and personally useful (p < 0.001) than participants randomized to UC. UC participants who completed the optional 4-week posttrial exercise program reported participation to be more rewarding (p = 0.008) and personally useful (p < 0.001) than UC participants who declined the program. LIMITATIONS: The study is limited by the lack of a validated measure of participant satisfaction, and the fact that the offer of participation in the posttrial exercise program to the UC group was not randomized. CONCLUSIONS:Lymphomapatients randomized to UC viewed it as less rewarding and personally useful despite being offered a 4-week posttrial exercise program. UC participants who completed the 4-week program reported personal satisfaction levels similar to the AET group; however, the causal direction of this association is unknown. Researchers should continue to evaluate participant satisfaction in exercise trials.
Authors: Andria R Morielli; Nawaid Usmani; Normand G Boulé; Diane Severin; Keith Tankel; Tirath Nijjar; Kurian Joseph; Kerry S Courneya Journal: Support Care Cancer Date: 2016-02-04 Impact factor: 3.603
Authors: Charlotte N Steins Bisschop; Kerry S Courneya; Miranda J Velthuis; Evelyn M Monninkhof; Lee W Jones; Christine Friedenreich; Elsken van der Wall; Petra H M Peeters; Anne M May Journal: PLoS One Date: 2015-03-27 Impact factor: 3.240
Authors: E L James; F G Stacey; K Chapman; A W Boyes; T Burrows; A Girgis; G Asprey; A Bisquera; D R Lubans Journal: BMC Cancer Date: 2015-10-15 Impact factor: 4.430
Authors: Kelcey A Bland; Sarah E Neil-Sztramko; Kendra Zadravec; Mary E Medysky; Jeffrey Kong; Kerri M Winters-Stone; Kristin L Campbell Journal: BMC Cancer Date: 2021-11-05 Impact factor: 4.430
Authors: Rebecca R Turner; Liz Steed; Helen Quirk; Rosa U Greasley; John M Saxton; Stephanie Jc Taylor; Derek J Rosario; Mohamed A Thaha; Liam Bourke Journal: Cochrane Database Syst Rev Date: 2018-09-19
Authors: Roxanne Gal; Evelyn M Monninkhof; Rolf H H Groenwold; Carla H van Gils; Desiree H J G van den Bongard; Petra H M Peeters; Helena M Verkooijen; Anne M May Journal: Trials Date: 2017-10-27 Impact factor: 2.279